Amrutanjan Health Care Q1 FY27 Net Sales Grow 9.48% to ₹102.97 Crore
Amrutanjan Health Care reported Q1 FY27 net sales of ₹102.97 crore, a 9.48% increase year-on-year. Profit after tax was ₹4.37 crore. The company commissioned a ₹150 crore sanitary napkin manufacturing facility in Telangana. New product launches contributed 4% to sales, with projections of ₹10 crore for wound care products. Management expects double-digit revenue and profit growth for FY27.
The announcement includes key financial performance metrics, significant capital expenditure in a new manufacturing facility, and strategic outlook, which are material information for investors.
The company reported positive sales growth, expansion through new manufacturing facilities and product launches, and positive outlook for the full year, despite some category-specific challenges and an exceptional item.
Amrutanjan Health Care Limited (AHCL) has announced its financial results for the quarter ended June 30, 2026 (Q1 FY27). The company reported a net sales growth of 9.48%, reaching ₹102.97 crore compared to ₹94.05 crore in the same quarter last year. Profit before exceptional item & tax stood at ₹8.10 crore, while profit before tax was ₹6.07 crore. Profit after tax was ₹4.37 crore.
The company's Women's Hygiene and Personal Care segment saw a net sales of ₹36.36 crore, a growth of 27.09%. The Comfy brand within this segment also experienced robust growth. OTC Products (Pain Management and Congestion) reported net sales of ₹57.26 crore. The Beverages segment, including Electro+ and Enerlyte, recorded net sales of ₹8.64 crore, a growth of 11.34%. Hydration drinks showed a growth of 13.88%.
AHCL has made significant investments, including a ₹150 crore greenfield sanitary napkin manufacturing facility in Telangana, which is its fifth manufacturing plant. This facility features two high-speed automated production lines from Japan. New product launches, such as Women's Razors, Men's Razors, Antiseptic Plaster, and Nasal Spray, contributed 4% to total AHCL sales in Q1 FY27, with projections of ₹10 crore for the Plastry line of wound care products.
Operations saw improvements with a 7% increase in the stockist network and a 9% rise in productive calls. Total lines sold increased by 20%, and effective outlet coverage grew by 8%.
An exceptional item of ₹202.75 lakh was recorded due to the payment of revised lease rent for leasehold land, a one-time impact as the land possession was handed over in May 2018. The management expects double-digit growth in revenue and operating profits for the full year, aiming to monetize the new Comfy plant and ensure profitability for the brand.
What to do with a filing like this
Amrutanjan Health Care Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Amrutanjan Health Care Limited. Read the original for the full detail.